Literature DB >> 11003709

Identification and characterization of PRKCBP1, a candidate RACK-like protein.

S C Fossey1, S Kuroda, J A Price, J K Pendleton, B I Freedman, D W Bowden.   

Abstract

The receptors for activated C-kinase (RACK) family of proteins function as anchors for activated protein kinase C (PKC) isoenzymes. Using a monoclonal antibody to RACK1 in the screening of a human hippocampus cDNA library, we identified a novel member of the RACK family, designated PRKCBP1. Immunoprecipitation assays performed with a GST-fused PRKCBP1 protein suggest the carboxy terminus of PRKCBP1 interacts specifically with PKCbetaI. Northern analysis detected a 3.1-kb PRKCBP1 transcript in all tissues examined including brain, heart, liver, lung, pancreas, skeletal muscle, kidney, and spleen. The PRKCBP1 gene has been localized to human Chromosome (Chr) 20q12-13.1. Several groups have reported evidence for genetic linkage of Type II diabetes to this region in Caucasian families. This localization, combined with the observation that abnormalities in the activation, translocation, and inhibition of PKC occur in the development of Type II diabetes, suggested that PRKCBP1 was a candidate for contributing to Type II diabetes. We determined the PRKCBP1 coding sequence is 1845 bp in length, dispersed over 9 exons, spanning approximately 34 kb of genomic DNA. SSCP analysis was used to screen PRKCBP1 coding regions for mutations or polymorphisms in 100 Caucasian Type II diabetics and 100 Caucasian unaffected individuals. A silent C/T transition (bp1413, Thr137) was present in 23% of both diabetic and control individuals. A C/T transition (bp198) was also identified in a single diabetic individual, which resulted in no coding change (Ser66). The results of this analysis suggest that PRKCBP1 coding variations are uncommon and do not contribute to Type II diabetes in the general population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11003709     DOI: 10.1007/s003350010174

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  17 in total

1.  Cloning, expression and genomic structure of a novel human GNB2L1 gene, which encodes a receptor of activated protein kinase C (RACK).

Authors:  Shu Wang; Jin-Zhong Chen; Zhen Zhang; Shaohua Gu; Chaoneng Ji; Rong Tang; Kang Ying; Yi Xie; Yumin Mao
Journal:  Mol Biol Rep       Date:  2003-03       Impact factor: 2.316

2.  Protein kinase C binding protein 1 inhibits hypoxia-inducible factor-1 in the heart.

Authors:  Kathryn J Schunke; Chad B Walton; David R Veal; Chrisy T Mafnas; Cynthia D Anderson; Allison L Williams; Ralph V Shohet
Journal:  Cardiovasc Res       Date:  2019-07-01       Impact factor: 10.787

3.  ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis.

Authors:  Yan Chen; Bo Zhang; Lei Bao; Lai Jin; Mingming Yang; Yan Peng; Ashwani Kumar; Jennifer E Wang; Chenliang Wang; Xuan Zou; Chao Xing; Yingfei Wang; Weibo Luo
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

4.  Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex.

Authors:  Hongjie Shen; Wenqi Xu; Rui Guo; Bowen Rong; Lei Gu; Zhentian Wang; Chenxi He; Lijuan Zheng; Xin Hu; Zhen Hu; Zhi-Ming Shao; Pengyuan Yang; Feizhen Wu; Yujiang Geno Shi; Yang Shi; Fei Lan
Journal:  Cell       Date:  2016-04-07       Impact factor: 41.582

5.  Increased myocardial expression of angiopoietin-2 in patients undergoing urgent surgical revascularization for acute coronary syndromes.

Authors:  Neil P Fam; Sara Arab; Filio Billia; Robin Han; Gerald Proteau; David Latter; Lee Errett; Daniel Bonneau; Rosemary Dunne; Peter P Liu; Duncan J Stewart
Journal:  Can J Cardiol       Date:  2010 Aug-Sep       Impact factor: 5.223

6.  Double duty: ZMYND8 in the DNA damage response and cancer.

Authors:  Fade Gong; Kyle M Miller
Journal:  Cell Cycle       Date:  2018-03-19       Impact factor: 4.534

Review 7.  Bromodomain biology and drug discovery.

Authors:  Nilesh Zaware; Ming-Ming Zhou
Journal:  Nat Struct Mol Biol       Date:  2019-10-03       Impact factor: 15.369

8.  The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.

Authors:  Anne M Galea; Vincent Murray
Journal:  Cancer Inform       Date:  2008-06-10

9.  Rare variants in NR2F2 cause congenital heart defects in humans.

Authors:  Saeed Al Turki; Ashok K Manickaraj; Catherine L Mercer; Sebastian S Gerety; Marc-Phillip Hitz; Sarah Lindsay; Lisa C A D'Alessandro; G Jawahar Swaminathan; Jamie Bentham; Anne-Karin Arndt; Jacoba Louw; Jacoba Low; Jeroen Breckpot; Marc Gewillig; Bernard Thienpont; Hashim Abdul-Khaliq; Christine Harnack; Kirstin Hoff; Hans-Heiner Kramer; Stephan Schubert; Reiner Siebert; Okan Toka; Catherine Cosgrove; Hugh Watkins; Anneke M Lucassen; Ita M O'Kelly; Anthony P Salmon; Frances A Bu'lock; Javier Granados-Riveron; Kerry Setchfield; Chris Thornborough; J David Brook; Barbara Mulder; Sabine Klaassen; Shoumo Bhattacharya; Koen Devriendt; David F Fitzpatrick; David I Wilson; Seema Mital; Matthew E Hurles
Journal:  Am J Hum Genet       Date:  2014-04-03       Impact factor: 11.025

10.  Fusion of ZMYND8 and RELA genes in acute erythroid leukemia.

Authors:  Ioannis Panagopoulos; Francesca Micci; Jim Thorsen; Lisbeth Haugom; Jochen Buechner; Gitte Kerndrup; Anne Tierens; Bernward Zeller; Sverre Heim
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.